PMID: 9438918Jan 24, 1998Paper

Alpha-2 adrenergic activity in perimenopausal women

Journal of Endocrinological Investigation
G Del RioA Velardo

Abstract

Lipid alterations and increased blood pressure may occur during perimenopause. No data are available in perimenopausal women on the alpha-2 adrenergic activity which affects norepinephrine secretion. We studied cardiovascular and catecholamine responses to clonidine (300 mg per os) in a group of 15 perimenopausal women (PeriMW) and in a control group of 13 premenopausal women (PreMW). Nine of the perimenopausal women were also studied after 4-month percutaneous estrogen replacement therapy (PeriMWE). Systolic and diastolic blood pressure (SBP, DBP), heart rate (HR), plasma norepinephrine (NE) and epinephrine (E) were evaluated before and at 120 min, 130 min, 140 min after clonidine administration. Basal values of SBP, DBP and HR were not different (F = 0.7, p = NS; F = 0.2, p = NS and F = 0.1, p = NS respectively) between PeriMW both before and after therapy and PreMW. Resting levels of E were similar in PreMW and in PeriMW before and during estrogen therapy (F = 0.8, p = NS); PeriMW showed higher basal NE levels both before and during estrogen therapy than PreMW (F = 12; p < 0.001). Clonidine administration decreased SBP, DBP and NE levels in PreMW, in PeriMW and in PeriMWE without any difference between the groups (F = 1.2, p...Continue Reading

References

Jul 8, 1978·British Medical Journal·D W SturdeeA D Crocker
Oct 1, 1976·Annals of Internal Medicine·W B KannelT Gordon
Apr 1, 1976·The Journal of Clinical Endocrinology and Metabolism·B M ShermanS G Korenman
May 1, 1991·British Journal of Pharmacology·L GandíaA G García
Aug 1, 1990·The American Journal of Clinical Nutrition·R F KushnerD A Schoeller
Mar 1, 1989·The Journal of Clinical Endocrinology and Metabolism·G Del RioL Della Casa
Jan 1, 1985·Annals of Internal Medicine·D S GoldsteinH R Keiser
Jul 1, 1985·The Journal of Clinical Investigation·D S GoldsteinI J Kopin
Mar 9, 1974·British Medical Journal·J R ClaydenP Pollard
Jan 1, 1980·Journal of Cardiovascular Pharmacology·W A Pettinger
Jul 1, 1984·The Journal of Clinical Endocrinology and Metabolism·R C VeithJ B Halter
Mar 1, 1981·Clinical Endocrinology·M G MetcalfJ H Livesey
Oct 1, 1982·The Journal of Clinical Endocrinology and Metabolism·A B Gustafson, R K Kalkhoff
Feb 1, 1981·Clinical Science·M EslerP Korner
Dec 1, 1981·Journal of Pharmacological Methods·D ArndtsH J Förster
Feb 1, 1995·The Journal of Clinical Endocrinology and Metabolism·M EslerD Seals
Sep 1, 1994·The Journal of Clinical Endocrinology and Metabolism·G Del RioI A MacDonald
Feb 1, 1994·Clinical Endocrinology·G Del RioA Velardo
Jul 1, 1993·Journal of Endocrinological Investigation·G Del RioL Della Casa
May 1, 1993·Diabetologia·S A AmielI A Macdonald
Jan 1, 1993·Baillière's Clinical Endocrinology and Metabolism·N E AvisK Vass

❮ Previous
Next ❯

Citations

Jul 8, 1999·European Journal of Pharmacology·D C ChenD N Krause
Mar 13, 2014·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Lorenzo GhiadoniStefano Taddei
Sep 13, 2018·Current Vascular Pharmacology·Evangelia MaretiDimitrios G Goulis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

© 2021 Meta ULC. All rights reserved